A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

BACKGROUND: The JAK inhibitor (JAKi) ruxolitinib is standard treatment for myelofibrosis (MF), but some patients are unresponsive. Pre-clinical and clinical data suggest that addition of a Hedgehog pathway inhibitor (HPI) to ruxolitinib might improve response. Vismodegib is an HPI approved for treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Couban, Stephen, Benevolo, Giulia, Donnellan, William, Cultrera, Jennifer, Koschmieder, Steffen, Verstovsek, Srdan, Hooper, Gregory, Hertig, Christian, Tandon, Maneesh, Dimier, Natalie, Malhi, Vikram, Passamonti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154811/
https://www.ncbi.nlm.nih.gov/pubmed/30249277
http://dx.doi.org/10.1186/s13045-018-0661-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154811/
https://www.ncbi.nlm.nih.gov/pubmed/30249277
http://dx.doi.org/10.1186/s13045-018-0661-x

Ejemplares similares